P1113 (DAIDS ID 11911): Phase I/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants
|Study Status||Study Restriction|
What is P1113?
P1113 is a Phase I/II, randomized, double-blind, placebo-controlled, safety, immunogenicity and dose-range finding study of the AERAS-404 tuberculosis vaccine in HIV-unexposed, HIV-uninfected, BCG-primed South African infants. The study is being conducted in collaboration with AERAS, Sanofi Pasteur, and Statens Serum Institut.
Sites where the study is implemented:
|CRS ID||Site Name||City||Country|
|No records returned.|
Clinical Trials Specialist: Anne Coletti